	US 12,344,846 B2
	Compositions and methods using CpG oligonucleotides
Howard Levine, Killington, VT (US); Nyron Khan, Flanders, NJ (US); Prashant Girinath, Arlington, MA (US); and Simon Talbot, Boston, MA (US)
Filed by Six Therapeutics Inc., Flanders, NJ (US)
Filed on Sep. 13, 2024, as Appl. No. 18/885,005.
Application 18/885,005 is a continuation of application No. PCT/US2023/084608, filed on Dec. 18, 2023.
Claims priority of provisional application 63/433,623, filed on Dec. 19, 2022.
Prior Publication US 2025/0002922 A1, Jan. 2, 2025
Int. Cl. C07H 21/02 (2006.01); A61K 9/00 (2006.01); A61P 17/02 (2006.01); C07H 21/04 (2006.01); C12N 15/117 (2010.01)

CPC C12N 15/117 (2013.01) [A61K 9/0014 (2013.01); A61P 17/02 (2018.01); C12N 2310/17 (2013.01); C12N 2310/315 (2013.01); C12N 2320/35 (2013.01)]

20 Claims

1. A composition comprising:

(i) a synthetic CpG oligonucleotide having the following sequence:

A*T*C*T*C*G*T*A*G*C*A*T*C*T*C*G*T*A*G*C (SEQ ID NO: 17);

A*T*C*T*C*G*G*A*G*C*A*T*C*T*C*G*G*A*G*C (SEQ ID NO: 19);

A*T*G*C*G*T*C*G*G*C*G*A*C*G*T*C*G*T*G*C (SEQ ID NO: 21);

T*A*G*C*G*T*C*G*A*C*G*A*C*G*T*C*G*A*T*G (SEQ ID NO: 22);

A*T*A*T*A*C*T*C*T*A*T*A*G*A*T*T*T*C*T*C (SEQ ID NO: 24),

A*T*C*T*CG*T*A*G*C*A*T*C*T*C*G*T*A*G*C (SEQ ID NO: 25);

A*T*C*T*CG*G*A*G*C*A*T*C*T*C*G*G*A*G*C (SEQ ID NO: 27);

A*T*G*C G*T*C*G*G*C*G*A*C*G*T*C*G*T*G*C (SEQ ID NO: 29); or

T*A*G*C/G*T*C*G*A*C*G*A*C*G*T*C*G*A*T*G (SEQ ID NO: 30), wherein * indicates a phosphorothioate group and indicates a phosphodiester group between a C and a G; and

(ii) an excipient, diluent, carrier, or any combination of these.